Husar E - Search Results

1

Simlukafusp alfa (FAP-IL2v) immunocytokine is a versatile combination partner for cancer immunotherapy.

Waldhauer I, Gonzalez-Nicolini V, Freimoser-Grundschober A, Nayak TK, Fahrni L, Hosse RJ, Gerrits D, Geven EJW, Sam J, Lang S, Bommer E, Steinhart V, Husar E, Colombetti S, Van Puijenbroek E, Neubauer M, Cline JM, Garg PK, Dugan G, Cavallo F, Acuna G, Charo J, Teichgräber V, Evers S, Boerman OC, Bacac M, Moessner E, Umaña P, Klein C. Waldhauer I, et al. Among authors: husar e. MAbs. 2021 Jan-Dec;13(1):1913791. doi: 10.1080/19420862.2021.1913791. MAbs. 2021. PMID: 33974508 Free PMC article.

2

PKPD Assessment of the Anti-CD20 Antibody Obinutuzumab in Cynomolgus Monkey is Feasible Despite Marked Anti-Drug Antibody Response in This Species.

Grimm HP, Schick E, Hainzl D, Justies N, Yu L, Klein C, Husar E, Richter WF. Grimm HP, et al. Among authors: husar e. J Pharm Sci. 2019 Nov;108(11):3729-3736. doi: 10.1016/j.xphs.2019.07.013. Epub 2019 Jul 25. J Pharm Sci. 2019. PMID: 31351865

3

Novel in Vivo and in Vitro Pharmacokinetic/Pharmacodynamic-Based Human Starting Dose Selection for Glofitamab.

Frances N, Bacac M, Bray-French K, Christen F, Hinton H, Husar E, Quackenbush E, Schäfer M, Schick E, Vyver AV, Richter WF. Frances N, et al. Among authors: husar e. J Pharm Sci. 2022 Apr;111(4):1208-1218. doi: 10.1016/j.xphs.2021.12.019. Epub 2021 Dec 22. J Pharm Sci. 2022. PMID: 34953862

4

Comparative assessment of immune complex-mediated hypersensitivity reactions with biotherapeutics in the non-human primate: Critical parameters, safety and lessons for future studies.

Kronenberg S, Husar E, Schubert C, Freichel C, Emrich T, Lechmann M, Giusti AM, Regenass F. Kronenberg S, et al. Among authors: husar e. Regul Toxicol Pharmacol. 2017 Aug;88:125-137. doi: 10.1016/j.yrtph.2017.06.004. Epub 2017 Jun 15. Regul Toxicol Pharmacol. 2017. PMID: 28624430

5

Hypersensitivity Reactions to Obinutuzumab in Cynomolgus Monkeys and Relevance to Humans.

Husar E, Solonets M, Kuhlmann O, Schick E, Piper-Lepoutre H, Singer T, Tyagi G. Husar E, et al. Toxicol Pathol. 2017 Jul;45(5):676-686. doi: 10.1177/0192623317723539. Toxicol Pathol. 2017. PMID: 28830332

6

A Framework Proposal to Follow-Up on Preclinical Convulsive Signals of a New Molecular Entity in First-in-Human Studies Using Electroencephalographic Monitoring.

Abt M, Dinklo T, Rothfuss A, Husar E, Dannecker R, Kallivroussis K, Peck R, Doessegger L, Wandel C. Abt M, et al. Among authors: husar e. Clin Pharmacol Ther. 2019 Nov;106(5):968-980. doi: 10.1002/cpt.1455. Epub 2019 May 31. Clin Pharmacol Ther. 2019. PMID: 30993670 Free PMC article. Review.

7

CSL-Tox: an open-source analytical framework for the comparison of short-term and long-term toxicity end points and assessing the need of chronic studies in drug development.

Naga D, Dimitrakopoulou S, Roberts S, Husar E, Mohr S, Booler H, Musvasva E. Naga D, et al. Among authors: husar e. Sci Rep. 2023 Sep 8;13(1):14865. doi: 10.1038/s41598-023-41899-4. Sci Rep. 2023. PMID: 37684321 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

7 results

Search Page